Pharmacist Mike Cavanagh presented on behalf of the Pharmacy Health Insurance Steering Coalition (PHISC), a joint initiative by the Canadian Life and Health Insurance Association, the Neighbourhood Pharmacies Association of Canada and the Canadian Pharmacists Association. PHISC is putting the finishing touches on a package that explains the pharmacy services that could be covered by […]
Benefits Canada’s 2015 Pharmacy Solutions In Drug Plan management wrapped up with a five-member panel that considered the future of drug benefits. As specialty drugs continue to grow their share of the market, it may be safe to assume that “new drugs aren’t simply going to be added to formularies, whether they’re specialty or otherwise,” […]
A U.S. judge has refused to dismiss an insider trading lawsuit filed by two pension funds against Quebec-based Valeant Pharmaceuticals and hedge fund manager Bill Ackman over their activities before last year’s failed attempt to acquire Botox-maker Allergan. District Judge David Carter of California ruled this week that the case filed on behalf of investors […]
Expensive biologics are driving up drug claims costs…but how can employers choose between saving a life and saving the drug plan for everyone?
Now that the marketplace has moved past the golden era of drug plan management, where one could do nothing and see cost trends level off (or decline), it comes as no surprise that fear is setting in as the reality of cost increases set in.
A national single-payer pharmacare program is unnecessary and will be costly for Canadian patients and taxpayers, a study says.
Congressional Democrats are pressing a Republican committee chairman to force a pharmaceutical company to turn over documents tied to price hikes imposed earlier this year.
NDP leader Tom Mulcair went to a Liberal-held riding today to announce he plans to work with the provinces to support universal prescription drug coverage—but the party is not classifying their promise as a national pharmacare plan.
Shire has made an unsolicited takeover bid of US$30 billion for biosciences company Baxalta, which was recently spun off from healthcare company Baxter International.
Teva Pharmaceutical has agreed to acquire Allergan's global generic pharmaceuticals business for US$40.5 billion.